This activity is supported by an unrestricted educational grant from United Therapeutics

Immunotherapy for High-Risk Neuroblastoma

Rajen Mody, MD MS
University of Michigan

Elizabeth Hollenkamp, BSN, RN
University of Michigan

Rhonda McDougall, PNP
University of Michigan

Erika Mora, PharmD
University of Michigan

Break through immunotherapy for High-Risk Neuroblastoma presents challenges in administration and symptom management, which requires interprofessional collaboration and family support.  This activity will present case studies that clearly define the complexities involved in treatment decisions, symptom management, guidelines for administration, and the role of the collaborative care to improve patient outcomes.


Download Podcast


Download Transcript


Download Slides


Download Slides & Transcripts


Related Material

What elements should be included in the education of patient and families receiving dinutuximab therapy?
What is the importance of an interprofessional approach in the management of a patient receiving dinutuximab therapy?
What is the mechanism of action for dinutuximab?
What are the biggest challenges of managing high-risk neuroblastoma?
What comorbidities should be taken into account before dosing with dinutuximab?
What are the black box warnings for dinutuximab?
For patients with neuroblastoma receiving immunotherapy, what pharmacologic treatment should be considered for pain management?
Why is pain viewed as a biopsychosocial phenomenon?
What are some modalities that can reduce or eliminate pain-associated suffering?
How do you identify a patient with high-risk neuroblastoma?
Why is an interprofessional approach and family centered care important to patients receiving this immunotherapy?

These CME/CE/CPE accredited activities are jointly provided by

JADPRO CE Logo Harborside Press Logo APSHO Logo Annenberg Logo
Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.